Evidence map›Paper›PMID 36883182›Full record

ArticleBiophysics2022

SARS-COV-2 Coronavirus Papain-like Protease PLpro as an Antiviral Target for Inhibitors of Active Site and Protein-Protein Interactions.

P V Ershov, E O Yablokov, Y V Mezentsev, G N Chuev, M V Fedotova, S E Kruchinin, A S Ivanov

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. How does NMR support SARS-CoV-2 protein-ligand interaction studies?Analytical and bioanalytical chemistry · 2026
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

P V ErshovInstitute of Biomedical Chemistry, 119121 Moscow, Russia.
E O YablokovInstitute of Biomedical Chemistry, 119121 Moscow, Russia.
Y V MezentsevInstitute of Biomedical Chemistry, 119121 Moscow, Russia.
G N ChuevInstitute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 142290 Pushchino, Moscow oblast Russia.
M V FedotovaKrestov Institute of Solution Chemistry, Russian Academy of Sciences, 153045 Ivanovo, Russia.
S E KruchininKrestov Institute of Solution Chemistry, Russian Academy of Sciences, 153045 Ivanovo, Russia.
A S IvanovInstitute of Biomedical Chemistry, 119121 Moscow, Russia.
Institute of Biomedical Chemistry · RUInstitute of Solution Chemistry · RUInstitute of Theoretical and Experimental Biophysics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The papain-like protease PLpro of the SARS-CoV-2 coronavirus is a multifunctional enzyme that catalyzes the proteolytic processing of two viral polyproteins, pp1a and pp1ab. PLpro also cleaves peptide bonds between host cell proteins and ubiquitin (or ubiquitin-like proteins), which is associated with a violation of immune processes. Nine structures of the most effective inhibitors of the PLpro active center were prioritized according to the parameters of biochemical (

Indexed as

inhibitorspapain-like proteasePLproprotein–protein interactionsSARS-CoV-2surface plasmon resonancevirus-host

Identifiers

PMID36883182
PMCPMC9984130
OpenAlexW4323064811

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.